The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Headline
The Department of Health and Human Services’ Office for Civil Rights Nov. 16 finalized changes to its HIPAA privacy rule standards, with the purposes of…
Headline
An FBI report released Nov. 13 details actions by cyber actors weaponizing ARTEX, an open-source, large language model-driven agentic artificial intelligence…
Headline
Brian Kaiser, supervisory special agent with the FBI’s Cyber Division, and Chad Beebe, deputy executive director of the American Society for Health Care…
Headline
The Food and Drug Administration is seeking feedback on a discussion paper released Nov. 6 on the benefits and risks of robotic medical devices with autonomous…
Headline
Federal agencies Nov. 5 issued a bulletin saying that they are aware of malicious cyber activity targeting industrial refrigeration and cold chain monitoring…
Headline
The AHA will host a webinar Nov. 3 at 1 p.m. ET to discuss the cybersecurity, compliance and operational risks that can emerge when end-of-life technology is…